Literature DB >> 2157579

Empirical Bayes estimates of subgroup effects in clinical trials.

C E Davis1, D P Leffingwell.   

Abstract

At the completion of a clinical trial it is often desirable to compare the treatments within subgroups of patients. The results of the subgroup analysis are usually reported for the subgroups within which sizable treatment differences are found. This practice can lead to an overestimate of the difference between treatments within the subgroups reported. One way of adjusting for this bias is to use empirical Bayes methods which shrink the extreme estimates toward the overall measure of treatment difference. Both point and interval estimates can be obtained. The computations are illustrated with an example using subgroup data from the Lipid Research Clinics Coronary Primary Prevention Trial.

Entities:  

Mesh:

Year:  1990        PMID: 2157579     DOI: 10.1016/0197-2456(90)90030-6

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  7 in total

1.  Meta-analysis and quality of evidence in the economic evaluation of drug trials.

Authors:  R J Simes; P P Glasziou
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

2.  Treatment effect heterogeneity for univariate subgroups in clinical trials: Shrinkage, standardization, or else.

Authors:  Ravi Varadhan; Sue-Jane Wang
Journal:  Biom J       Date:  2015-10-20       Impact factor: 2.207

3.  Estimation of treatment effect in a subpopulation: An empirical Bayes approach.

Authors:  Changyu Shen; Xiaochun Li; Jaesik Jeong
Journal:  J Biopharm Stat       Date:  2015-05-26       Impact factor: 1.051

4.  Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study.

Authors:  Maria Luisa Brandi; Suzanne Jan de Beur; Karine Briot; Thomas Carpenter; Hae Il Cheong; Martine Cohen-Solal; Rachel K Crowley; Richard Eastell; Yasuo Imanishi; Erik A Imel; Steven W Ing; Karl Insogna; Nobuaki Ito; Kassim Javaid; Peter Kamenicky; Richard Keen; Takuo Kubota; Robin H Lachmann; Farzana Perwad; Pisit Pitukcheewanont; Anthony Portale; Stuart H Ralston; Hiroyuki Tanaka; Thomas J Weber; Han-Wook Yoo; Wei Sun; Angela Williams; Annabel Nixon; Yasuhiro Takeuchi
Journal:  Calcif Tissue Int       Date:  2022-08-04       Impact factor: 4.000

Review 5.  Gender differences in pharmacokinetics.

Authors:  C H Gleiter; U Gundert-Remy
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

6.  Antihypertensive treatment and US trends in stroke mortality, 1962 to 1980.

Authors:  M Casper; S Wing; D Strogatz; C E Davis; H A Tyroler
Journal:  Am J Public Health       Date:  1992-12       Impact factor: 9.308

7.  Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.

Authors:  Scott M Berry; Kristine R Broglio; Susan Groshen; Donald A Berry
Journal:  Clin Trials       Date:  2013-08-27       Impact factor: 2.486

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.